New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
05:55 EDTLMNX, LMNX, LMNX, LMNX, LMNX, BIIB, BIIB, BIIB, BIIB, BIIB, VSTM, VSTM, VSTM, VSTM, VSTM, IMUC, IMUC, IMUC, IMUC, IMUC, PFE, PFE, PFE, PFE, PFE, AMGN, AMGN, AMGN, AMGN, AMGN, JNJ, JNJ, JNJ, JNJ, JNJ, REGN, REGN, REGN, REGN, REGNCambridge Healthtech Institute to host a conference
Molecular Med: Tri-Con 2013 is being held in San Francisco on February 11-15.
News For LMNX;BIIB;VSTM;IMUC;PFE;AMGN;JNJ;REGN From The Last 14 Days
Check below for free stories on LMNX;BIIB;VSTM;IMUC;PFE;AMGN;JNJ;REGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
April 15, 2014
07:49 EDTJNJJohnson & Johnson reports Q1 Domestic sales up 2.2%; Intl sales up 4.5%
Subscribe for More Information
07:47 EDTJNJJohnson & Johnson raises FY14 EPS to $5.80-$5.90, consensus $5.83
Subscribe for More Information
07:46 EDTJNJJohnson & Johnson reports Q1 adjusted EPS $1.54, consensus $1.48
Reports Q1 revenue $18.1B, consensus $18.0B
06:32 EDTPFE, JNJPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 14, 2014
15:17 EDTJNJNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Johnson & Johnson (JNJ), consensus $1.48; Coca-Cola (KO), consensus 44c; Charles Schwab (SCHW), consensus 22c; Northern Trust (NTRS), consensus 78c; Comerica (CMA), consensus 72c; Westamerica (WABC), consensus 58c; Comverse (CNSI), consensus 49c; Pep Boys (PBY), consensus 5c.
13:25 EDTJNJEarnings Preview: J&J looking for another strong performance in pharmaceuticals
Subscribe for More Information
10:02 EDTJNJOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:46 EDTBIIBBiogen hugs support at critical technical juncture, levels to watch
Subscribe for More Information
09:05 EDTPFEGlycoMimetics presents GMI-1070 data
Subscribe for More Information
07:33 EDTBIIBBiogen to present Plegridy, Tecfidera data at AAN annual meeting
Subscribe for More Information
05:56 EDTJNJJohnson & Johnson downgraded to Hold from Buy at Jefferies
Jefferies downgraded its rating on Johnson & Johnson (JNJ) to Hold citing the recent outperformance of shares. The firm keeps a $105 price target for the stock.
April 11, 2014
18:44 EDTJNJJ&J halting development of Botox competitor, WSJ says
Subscribe for More Information
10:15 EDTBIIBBiogen heads for test of $280 area
The shares are heading lower after an early bounce attempt and are now just above the session low at $280.13. As noted yesterday, a break below $280 would confirm topping in the shares. Support below $280 is at $273.45. Resistance is at $285.
07:19 EDTPFEAcura Pharma to host conference call
Subscribe for More Information
April 10, 2014
15:13 EDTBIIBBiogen tumbles, nearing important test of support
Subscribe for More Information
12:12 EDTVSTMVerastem management to meet with Roth Capital
Subscribe for More Information
09:00 EDTBIIBBiogen May volatility elevated at 43 into Q1 and revenue outlook
Subscribe for More Information
07:31 EDTBIIBBiogen names Adam Koppel as SVP, Chief Strategy Officer
Subscribe for More Information
07:08 EDTBIIBBiogen announces positive top-line efficacy, safety results from Phase 3 trial
Biogen Idec and Swedish Orphan Biovitrum AB released positive top-line results of the Kids A-LONG Phase 3 clinical study that evaluated the safety and efficacy of Eloctate, an investigational recombinant factor VIII Fc fusion protein product candidate, in children with severe haemophilia A. Eloctate was generally well-tolerated and no inhibitors were detected. Efficacy analyses showed twice-weekly prophylactic dosing with Eloctate maintained low bleeding rates in children.
06:17 EDTPFEAcura Pharma announces return of product rights from Pfizer
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use